Connor Clark & Lunn Investment Management Ltd. Increases Stock Holdings in STAAR Surgical (NASDAQ:STAA)

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in STAAR Surgical (NASDAQ:STAA - Free Report) by 118.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 65,436 shares of the medical instruments supplier's stock after purchasing an additional 35,422 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.13% of STAAR Surgical worth $1,589,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. State Street Corp boosted its holdings in STAAR Surgical by 0.5% in the third quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier's stock valued at $72,092,000 after purchasing an additional 10,430 shares in the last quarter. Geode Capital Management LLC boosted its holdings in STAAR Surgical by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier's stock valued at $43,641,000 after purchasing an additional 31,212 shares in the last quarter. Yunqi Capital Ltd boosted its holdings in STAAR Surgical by 48.9% in the fourth quarter. Yunqi Capital Ltd now owns 767,413 shares of the medical instruments supplier's stock valued at $18,640,000 after purchasing an additional 252,113 shares in the last quarter. Defender Capital LLC. boosted its holdings in STAAR Surgical by 3.5% in the fourth quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier's stock valued at $17,041,000 after purchasing an additional 23,950 shares in the last quarter. Finally, American Capital Management Inc. boosted its holdings in STAAR Surgical by 42.9% in the third quarter. American Capital Management Inc. now owns 512,813 shares of the medical instruments supplier's stock valued at $19,051,000 after purchasing an additional 154,037 shares in the last quarter. 96.70% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 8,221 shares of the company's stock in a transaction that occurred on Thursday, January 16th. The shares were purchased at an average price of $21.50 per share, with a total value of $176,751.50. Following the completion of the acquisition, the insider now directly owns 10,878,007 shares of the company's stock, valued at approximately $233,877,150.50. The trade was a 0.08 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have acquired 1,036,187 shares of company stock valued at $17,239,548 over the last quarter. Company insiders own 1.00% of the company's stock.

Analysts Set New Price Targets

STAA has been the subject of a number of research reports. StockNews.com cut STAAR Surgical from a "hold" rating to a "sell" rating in a research note on Thursday, February 13th. Mizuho cut STAAR Surgical from an "outperform" rating to a "neutral" rating and reduced their price objective for the company from $45.00 to $17.00 in a research note on Wednesday, February 12th. BTIG Research cut STAAR Surgical from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 12th. Stephens reiterated an "equal weight" rating and issued a $17.00 price objective on shares of STAAR Surgical in a research note on Tuesday, March 18th. Finally, Canaccord Genuity Group reduced their price objective on STAAR Surgical from $28.00 to $17.00 and set a "hold" rating for the company in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $25.29.

STAAR Surgical Trading Down 1.1 %

Shares of STAAR Surgical stock traded down $0.20 during trading hours on Friday, hitting $17.72. 1,641,674 shares of the company were exchanged, compared to its average volume of 765,536. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68. The business has a 50-day moving average of $19.87 and a 200-day moving average of $25.66. The stock has a market capitalization of $874.04 million, a price-to-earnings ratio of -43.22 and a beta of 0.66.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.